Avalo Therapeutics (AVTX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Avalo Therapeutics

NasdaqCM•Healthcare•Biotechnology

$17.59-0.63(-0.03%)Market open

Market Cap

$702.86M

P/S

11913.0x

P/B

1.6x

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

How this company scores

WeakMetricSide Score: 27/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (2/25).

Profitability6/25

Growth2/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality4/25

Strengths

Interest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 1.2x5y range 1.2x – 1.2x

P/S · 11913.0x5y range 1.3x – 97566.5x

Currently above its 20-quarter median.

P/B · 1.6x5y range 0.3x – 34005.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $702.86M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $59,000
Q. Revenue: $0
TTM EBITDA: $-91.25M
TTM Op. Income: $-91.36M
Q. Op. Income: $-31.52M
TTM Net Income: $-100.33M
Q. Net Income: $-36.36M
EPS: $-0.83
Shares Out.: $43.60M

$59,000 in TTM revenue declined 86.6% YoY, reaching $0 last quarter. TTM EBITDA of $-91.25M and TTM operating income of $-91.36M show growth is flowing through to the bottom line. However, net income is negative at $100.33M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 87% — a steady trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -3151700000.0%
Net Margin: -3635800000.0%

Op. margin of -3151700000.0% is down 1220100000.0% YoY — costs are rising relative to revenue. Net margin at -3635800000.0% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 11913.0x
P/B Ratio: 1.6x

P/S of 11913.0x and P/B of 1.6x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $490.78M
Cash: $85.38M
Long-Term Debt: N/A
Book Value: $448.66M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-19.99M
TTM Free Cash Flow: $-68.29M
FCF Margin: -115745.8%
FCF / Net Income: 0.7

TTM FCF of $-68.29M on $-19.99M in operating cash flow. The FCF / Net Income ratio of 0.7x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.